Study type: Human research · Status: Verified against declared source
Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future.
Romanian journal of ophthalmology · 2025
Study scale: Not reported
Abstract only: Open source record
Product or molecular entity relationships
- SS-31: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
The introduction of AREDS and AREDS2 supplementation represents one of the most critical advances in preventing the progression of age-related macular degeneration (AMD) [6].
Methods
This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment.
Scale or participants
Not reported in the reviewed source.
Key findings
This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment.
Limitations and uncertainty
Modern therapeutic approaches for dry AMD provide promising avenues to slow disease progression and protect vision.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.